



Therapeutic Potential of Nerve Growth Factor Signaling Blockers against Castration-Resistant Prostate Cancers

Guest Editor:

Dr. Shian-Ren Lin

FullHope Biomedical Co. Ltd.,
New Taipei City, 241405, Taiwan

Deadline for manuscript
submissions:

closed (31 October 2023)

Message from the Guest Editor

Recent studies have demonstrated that activated NGF signaling mediates treatment-mediated neuroendocrine transformation, an advanced CRPC sub-phenotype with high mortality and low responding rate to conventional treatment. Furthermore, gastroenteropancreatic neuroendocrine patients benefit from receiving NGF signaling blockers and immune checkpoint inhibitors. Additionally, the NGF receptor inhibitor reduces the tumor growth of androgen-independent prostate cancer cell lines in vitro. These studies imply that modulating the activity of NGF signaling may benefit the tumor control of CRPC and neuroendocrine tumors, which is not evaluated yet. This Special Issue aims to collect studies on the therapeutic potential of NGF blockers on CRPC, such as the discovery of new NGF blockers or combinations, clinical trials of NGF signaling blockers against CRPCs, and reviews for stratifying CRPC patients with clinical benefit from NGF signaling blockers.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)